Management of INR 5 on Warfarin
For a patient on warfarin with an INR of 5 who is not bleeding and has no high-risk bleeding factors, omit the next 1-2 doses of warfarin and restart at a lower dose when the INR approaches therapeutic range. 1
Risk Stratification is Critical
An INR of 5 sits at a critical threshold where bleeding risk begins to rise sharply, though the absolute daily risk remains relatively low 1. Your management decision hinges on three key factors:
- Active bleeding: Any signs of bleeding (major or minor)?
- Bleeding risk factors: Age ≥65 years, history of stroke or GI bleeding, renal insufficiency, anemia, concomitant antiplatelet agents 1
- Need for urgent procedures: Surgery or dental extraction planned?
Management Algorithm
For Low-Risk Patients (No bleeding, no risk factors):
Omit the next 1-2 doses of warfarin and restart at a reduced dose when INR falls into therapeutic range (typically 2.0-3.0). This conservative approach allows the INR to drift down naturally over 24-48 hours without causing warfarin resistance 1.
- Monitor INR in 24 hours
- Resume warfarin at 10-20% lower weekly dose
- Recheck INR within 3-5 days after resumption
For High-Risk Patients (Bleeding risk factors present):
Omit the next dose AND give oral vitamin K₁ 1.0-2.5 mg 1. This approach is specifically recommended when patients have increased bleeding risk, as it more rapidly lowers the INR to <5 within 24 hours compared to simply withholding warfarin 1.
- Oral vitamin K₁ is predictably effective and safer than IV or subcutaneous routes 1
- Avoid IV vitamin K₁ unless rapid reversal is critical (risk of anaphylaxis) 1
- Subcutaneous vitamin K₁ has unpredictable and delayed response 1
- Recheck INR in 24 hours
If Urgent Surgery/Dental Procedure Needed:
Give oral vitamin K₁ 2-5 mg, anticipating INR reduction within 24 hours 1. An additional 1-2 mg can be given if INR remains elevated after 24 hours 1.
Critical Pitfalls to Avoid
Do not use high-dose vitamin K₁ (10 mg) for an INR of 5. High doses may lower the INR excessively and cause warfarin resistance lasting up to a week, complicating reinitiation of therapy 1. The guideline evidence is clear: 1.0-2.5 mg is sufficient for INR between 4-10 1.
Do not give fresh frozen plasma or prothrombin complex concentrate unless there is active major bleeding. These are reserved for INR ≥9 with serious bleeding or life-threatening situations 1.
Monitoring Strategy
- Immediate: Recheck INR in 24 hours after intervention
- Short-term: Once INR approaches therapeutic range, resume warfarin at reduced dose (typically 10-20% reduction in weekly dose)
- Follow-up: Check INR 3-5 days after resuming warfarin, then weekly until stable 2
Special Considerations
The evidence consistently shows that even with an INR of 5, the absolute daily bleeding risk remains low in patients without active bleeding or risk factors 1. This supports the conservative "omit and observe" approach in low-risk patients rather than reflexively administering vitamin K, which can complicate subsequent warfarin dosing.